Gini F. Fleming

ORCID: 0000-0003-2845-4023 · 3 papers in corpus · active 2010-2021

Study types

  • article 2
  • review 1
article 2021
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
·doi:10.1200/jco.2021.39.15_suppl.tps5609

TPS5609 Background: Despite significant strides in understanding the molecular pathogenesis of EC, there remain few effective therapies for recurrent disease. Deeper insight into the roles of disordered tumor vasculature and HIF1α- and VEGF…

article 2013
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma
·doi:10.17925/ohr.2013.09.1.41

Hormonal therapies such as progestins have only modest activity in the treatment of advanced endometrial cancer. Mechanisms of resistance to progestin therapy are not well understood. However, activation of the PI3K/AKT/mTOR pathway has bee…

review 2010
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma
·doi:10.17925/ee.2013.09.01.18

Hormonal therapies such as progestins have only modest activity in the treatment of advanced endometrial cancer. Mechanisms of resistance to progestin therapy are not well understood. However, activation of the PI3K/AKT/mammalian target of …